Treatment of Klebsiella Pneumoniae Carbapenemase (KPC) infections: a review of published case series and case reports
Top Cited Papers
Open Access
- 1 January 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in Annals of Clinical Microbiology and Antimicrobials
- Vol. 11 (1), 32
- https://doi.org/10.1186/1476-0711-11-32
Abstract
The emergence of Klebsiella pneumoniae carbapenemases (KPCs) producing bacteria has become a significant global public health challenge while the optimal treatment remains undefined. We performed a systematic review of published studies and reports of treatment outcomes of KPC infections using MEDLINE (2001–2011). Articles or cases were excluded if one of the following was fulfilled: no individual patient data provided, no treatment regimen specified, no treatment outcome specified, report of colonization, or greater than three antibiotics were used to treat the KPC infection. Data extracted included patient demographics, site of infection, organism, KPC subtype, antimicrobial therapy directed at KPC-infection, and treatment outcome. Statistical analysis was performed in an exploratory manner. A total of 38 articles comprising 105 cases were included in the analysis. The majority of infections were due to K. pneumoniae (89%). The most common site of infection was blood (52%), followed by respiratory (30%), and urine (10%). Forty-nine (47%) cases received monotherapy and 56 (53%) cases received combination therapy directed at the KPC-infection. Significantly more treatment failures were seen in cases that received monotherapy compared to cases who received combination therapy (49% vs 25%; p= 0.01). Respiratory infections were associated with higher rates of treatment failure with monotherapy compared to combination therapy (67% vs 29% p= 0.03). Polymyxin monotherapy was associated with higher treatment failure rates compared to polymyxin-based combination therapy (73% vs 29%; p= 0.02); similarly, higher treatment failure rates were seen with carbapenem monotherapy compared to carbapenem-based combination therapy (60% vs 26%; p= 0.03). Overall treatment failure rates were not significantly different in the three most common antibiotic-class combinations: polymyxin plus carbapenem, polymyxin plus tigecycline, polymyxin plus aminoglycoside (30%, 29%, and 25% respectively; p=0.6). In conclusion, combination therapy is recommended for the treatment of KPC infections; however, which combination of antimicrobial agents needs to be established in future prospective clinical trials.This publication has 72 references indexed in Scilit:
- Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination TherapyClinical Infectious Diseases, 2012
- Colistin-Resistant, Klebsiella pneumoniae Carbapenemase (KPC)-Producing Klebsiella pneumoniae Belonging to the International Epidemic Clone ST258Clinical Infectious Diseases, 2011
- Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time–kill assayInternational Journal of Antimicrobial Agents, 2011
- Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patientsInternational Journal of Antimicrobial Agents, 2010
- An Outbreak of Infection due to β‐LactamaseKlebsiella pneumoniaeCarbapenemase 2–ProducingK. pneumoniaein a Greek University Hospital: Molecular Characterization, Epidemiology, and OutcomesClinical Infectious Diseases, 2010
- Risk Factors and Clinical Impact of Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniaeInfection Control & Hospital Epidemiology, 2009
- Emergence of blaKPC-containing Klebsiella pneumoniae in a long-term acute care hospital: a new challenge to our healthcare systemJournal of Antimicrobial Chemotherapy, 2009
- Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenemDiagnostic Microbiology and Infectious Disease, 2009
- Outbreak of infections due to KPC-2-producing Klebsiella pneumoniae in a hospital in Crete (Greece)Journal of Infection, 2009
- Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USAJournal of Antimicrobial Chemotherapy, 2009